MedWatch

Abbvie to acquire Botox-maker – analysts and investors are skeptical

US drug group Abbvie celebrates its deal to buy Botox-manufacturer Allergan but analysts question the company's reasoning. The shareholders, who were not involved in the decision, punish the company with a 16 percent's decline in the share price.

Foto: Brendan McDermid/Reuters

A new giant in the medical industry is on the way after the acquisition deal between US drug group Abbvie and Irish-based Botox-maker Allergan.

However, shareholders and analysts are not as excited by the proposed birth of Abbergan, or Allervie if you prefer, as the companies themselves. The reactions to Abbvie's offer to acquire Allergan for USD 63 billion have been predominantly negative.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier